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Abstract
Previous studies have shown that exogenous ATP (>1µM) prevents bone formation in vitro by blocking mineralisation
of the collagenous matrix. This effect is thought to be mediated via both P2 receptor-dependent pathways and a
receptor-independent mechanism (hydrolysis of ATP to produce the mineralisation inhibitor pyrophosphate, PPi).
Osteoblasts are also known to release ATP constitutively. To determine whether this endogenous ATP might exert
significant biological effects, bone-forming primary rat osteoblasts were cultured with 0.5-2.5U/ml apyrase (which
sequentially hydrolyses ATP to ADP to AMP + 2Pi). Addition of 0.5U/ml apyrase to osteoblast culture medium
degraded extracellular ATP to <1% of control levels within 2 minutes; continuous exposure to apyrase maintained
this inhibition for up to 14 days. Apyrase treatment for the first 72 hours of culture caused small decreases (≤25%) in
osteoblast number, suggesting a role for endogenous ATP in stimulating cell proliferation. Continuous apyrase
treatment for 14 days (≥0.5U/ml) increased mineralisation of bone nodules by up to 3-fold. Increases in bone
mineralisation were also seen when osteoblasts were cultured with the ATP release inhibitors, NEM and brefeldin A,
as well as with P2X1 and P2X7 receptor antagonists. Apyrase decreased alkaline phosphatase (TNAP) activity by up
to 60%, whilst increasing the activity of the PPi-generating ecto-nucleotide pyrophosphatase/phosphodiesterases
(NPPs) up to 2.7-fold. Both collagen production and adipocyte formation were unaffected. These data suggest that
nucleotides released by osteoblasts in bone could act locally, via multiple mechanisms, to limit mineralisation.
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Introduction
Adenosine triphosphate (ATP) has long been recognized for
its role in intracellular energy metabolism; however, it is also an
important extracellular signalling molecule. The potent actions
of ATP were first described in 1929, yet it was 1972 before the
concept of purinergic neurotransmission was proposed [1].
Extracellular nucleotides, signalling via purinergic receptors,
are now known to participate in a wide number of biological
processes. The receptors for purines and pyrimidines are
classified into two groups; P1 receptors and P2 receptors.
There are four P1 receptor subtypes (A1, A2a, A2b, A3); these
receptors are G-protein coupled and activated by adenosine.
The P2 receptors respond to nucleotides including ATP,
adenosine diphosphate (ADP), uridine triphosphate (UTP) and
uridine diphosphate (UDP) and are further subdivided into the
P2X ligand-gated ion channels and the P2Y G-protein-coupled
receptors [2,3]. To date, seven P2X receptors (P2X1-7) and
eight P2Y receptors (P2Y1,2,4,6,11-14) have been identified; each
receptor has been cloned, characterised and displays distinct
pharmacology and tissue expression [4,5].
The expression of multiple P2 receptors by bone cells has
been widely reported and knowledge about the functional
effects of extracellular nucleotides in bone has increased
considerably in recent years (see reviews [6–9]). In
osteoblasts, the bone forming cells, extracellular nucleotides
have been reported to stimulate proliferation [10], induce
membrane blebbing [11], modulate responses to systemic
factors such as PTH [12,13] and stimulate the production of
lipid mediators [14]. Recent studies have shown that purinergic
signalling may also play a role in regulating bone turnover [15]
and the differentiation of mesenchymal stem cells into
osteoblasts or adipocytes [16,17]. Furthermore clopidogrel, a
P2Y12 receptor antagonist widely prescribed to reduce the risk
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of heart attack and stroke, inhibits bone cell function in vitro
and decreases trabecular bone in vivo [18]. We have
demonstrated that ATP and UTP, signalling via the P2Y2
receptor, strongly inhibit bone mineralisation and osteoblast
alkaline phosphatase (TNAP) activity [19,20]. Furthermore, a
recent study using ATP analogues demonstrated that P2X1
and P2X7 receptors are also involved in the regulation of bone
mineralisation by extracellular nucleotides [21].
The ATP concentration in cell cytosol is between 2mM and
5mM. Following membrane damage or necrosis, all cells
can release ATP into the extracellular environment, which can
then act in an autocrine/paracrine manner to influence local
purinergic signalling. Controlled ATP release has been
demonstrated from numerous excitatory and non-excitatory
cells. In the bone microenvironment, osteoblasts [22–26],
osteoclasts [27] and MLO-Y4 osteocyte-like cells [28] have all
been shown to constitutively release ATP.
Once released, nucleotides are rapidly broken down by an
extracellular hydrolysis cascade. Molecular and functional
characterisation has shown there are four families of ecto-
nucleotidases: (1) the NTPdases (ecto-nucleoside triphosphate
diphosphohydrolase); (2) the NPPs (ecto-nucleotide
pyrophosphatase/phosphodiesterase); (3) alkaline
phosphatases and, (4) ecto-5’-nucleotidase [29]. Many ecto-
nucleotidases have overlapping specificities. For example,
NTPdases catalyse the reactions: nucleotide triphosphate
(NTP) → nucleotide diphosphate (NDP) + phosphate (Pi) and
NDP → nucleotide monophosphate(NMP) + phosphate (Pi),
whereas NPPs hydrolyse NTP → NMP + pyrophosphate(PPi)
or NDP → NMP + Pi. Thus, the combined activities of these
ecto-enzymes limit the actions of extracellular nucleotides to
cells within close proximity of the release site. Osteoblasts
express three members of the NPP family (NPP1-3) [20,30,31]
and at least six members of the NTPdase family (NTPdase 1-6)
[32]. This hydrolysis of ATP and other NTPs by NPPs is
particularly important in bone because the product, PPi, is the
key, local physicochemical inhibitor of mineralisation [33,34].
The NTPs, CTP and GTP (which are not P2 receptor agonists
but are hydrolysed to produce PPi), also inhibit bone formation
without affecting TNAP activity [20]. Furthermore, osteoblastic
NPP activity generates significant concentrations of PPi in vitro
[20,21]. Thus, nucleotide triphosphates can exert a dual
inhibitory action on bone mineralisation via both P2 receptor-
mediated signalling and direct hydrolysis to PPi.
Apyrase (NTPDase 1, EC 3.6.1.5) has a broad spectrum of
catalytic activity, sequentially hydrolysing NTPs to their
corresponding NDPs and Pi, and NDPs to their corresponding
NMP and Pi [29]. Addition of apyrase to culture medium will
rapidly degrade any extracellular nucleotides present, therefore
making it a useful tool for studying purinergic signalling in vitro.
The aim of this study was to determine how osteoblast growth,
differentiation and function are regulated by endogenous
purinergic signalling under normal conditions.
Materials and Methods
Reagents
All tissue culture reagents were purchased from Life
Technologies (Paisley, UK); unless otherwise mentioned, other
reagents were obtained from Sigma Aldrich (Poole, Dorset,
UK). Molecular biology reagents were purchased from Life
Technologies (Paisley, UK) and all primers were from MWG
Biotech (Ebersberg, Germany).
Osteoblast cell culture
Primary rat osteoblast cells were obtained from 2-day-old
neonatal Sprague-Dawley rats euthanised by cervical
dislocation, as described previously [35]. All animal
experiments were approved by the University College London
Animal Users Committee and the animals were maintained in
accordance with the UK Home Office guidelines for the care
and use of laboratory animals.
Osteoblasts were cultured in the presence of apyrase
(0.5-2.5U/ml) to determine the effect on cell proliferation,
differentiation, function and ecto-nucleotidase activity. Unless
stated, experiments were carried out at 2 time points during the
osteoblast culture; day 7, which represents differentiating
osteoblasts, and day 14 (mature, bone forming osteoblasts).
The effect of vesicular exocytosis inhibitors (1nM-10µM N-
ethylmaleimide (NEM), brefeldin A, monensin) and P2 receptor
antagonists (Ro-0437626, NF279, PPNDS, AZ10606120,
A740003, A804598) on osteoblast function was also
investigated. All experiments were carefully pH-controlled
because bone mineralisation is extremely sensitive to inhibition
by acidosis [36].
Bone nodule formation and TNAP expression by osteoblasts
cultured in 24-well plates was measured as described
previously [19,35].
Measurement of extracellular ATP
Prior to measurement of ATP levels, culture medium was
removed, cell layers washed and cells incubated with serum-
free DMEM (1ml/well) for 1 hour. To determine how rapidly
apyrase hydrolysed extracellular ATP, samples were taken at
regular intervals for up to 10 minutes after addition of apyrase
(0.5U/ml). The longer term effects of apyrase on ATP levels
were measured in osteoblast cultures treated with apyrase for
4, 7 or 14 days. All samples were immediately snap-frozen on
dry ice for later ATP quantification. ATP release was measured
luminetrically using the luciferin-luciferase assay as described
previously [25].
Cell number and viability assay
Osteoblast were seeded at 2.5 x 104 cells/well and cell
number measured at 24, 48, and 72 hours and 7 days after
plating using the CytoTox 96® non-radioactive cytotoxicity
assay (Promega UK, Southampton, UK). This assay quantifies
cellular lactate dehydrogenase (LDH), a stable cytosolic
enzyme that is released on cell lysis. LDH oxidises lactate into
pyruvate, generating NADH, which is then used to convert a
Endogenous ATP and Osteoblasts
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tetrazolium salt into a red formazan product in proportion to the
number of lysed cells.
Cell supernatants were collected to determine medium LDH
levels (cell viability). To establish total cellular LDH levels, cells
were lysed with 1% Triton X-100 in water (lysis buffer, 15µl/ml
of medium) for 1 hour. The LDH content of the supernatants
and cell lysates were measured colorimetrically (490 nm) (EL
X800 plate reader, Bio-tek International) as per manufacturer’s
instructions. A standard curve for determination of cell numbers
was constructed using cells seeded at 102 to 106/well. Manual
cell counts were performed in parallel for assay validation. By
expressing medium LDH as a percentage of the total cellular
LDH cell viability could be also calculated.
Determination of TNAP and total NPP activity
The TNAP activity of cell lysates was determined
colorimetrically (Bio-Tek EL X800 plate reader, Fisher Scientific,
Loughborough, UK) using a commercially available kit (Biotron
Diagnostics, California, USA); this assay uses p-nitrophenyl
phosphate as a substrate, which in the presence of TNAP, is
converted to the yellow chromogen p-nitrophenyl. Osteoblast
TNAP activity was measured after 7 and 14 days of culture.
Cell layers were washed and cells harvested using a scraper
(n=6) followed by sonication at 4°C and centrifugation at 500 x
g. The supernatant was collected and stored at 4°C until
assaying at pH 9.8.
The assay used to measure total NPP activity was based on
the method originally described by Razzell and Khorana [37].
Briefly, cells were lysed in a buffer containing 1% Triton x 100
in 0.2M Tris base with 1.6 mM MgCl2, pH 8.1. Following
centrifugation at 500 x g, the NPP activity of collected
supernatants was measured using 5mM p-nitrophenyl-
thymidine 5’-monophosphate as a substrate. Total protein in
cell lysates was determined using the Bradford assay (Sigma
Aldrich, Poole, UK).
Measurement of collagen production
To measure soluble collagen production osteoblasts were
transferred to medium containing 5% FCS, 2mM β-
glycerophosphate, 50µg/ml ascorbic acid, 10nM
dexamethasone and the lysyl oxidase inhibitor β-
aminoproponitrile (50µg/ml) for the final 24 hours of culture.
The concentration of collagen accumulated in the tissue culture
medium was assayed using a Sirius red dye-based kit (Sircol
soluble collagen assay, Biocolor Ltd, Newtownabbey, UK)
according to the manufacturer’s instructions. Total protein
concentration in lysates was determined using the Bradford
assay.
Oil red O staining for adipocytes
This assay was based on the method originally described by
Ramirez-Zacarias [38]. Cells were fixed with 2.5%
glutaraldehyde for 5 min, washed with 60% isopropanol and
allowed to air dry. The oil red O stock solution (0.35% w/v in
isopropanol) was diluted to a working solution (6 parts stock: 4
parts dH2O) and added to the fixed cells for 10 min. Following
four washes with distilled water, cell layers were allowed to dry
completely. The amount of oil red O staining was quantified by
eluting the stain with 100% isopropanol (750µl/well for 10 min)
and reading the optical density at 490nm.
Total RNA extraction and Dnase treatment
Osteoblasts were cultured with apyrase in 6-well trays for 7
and 14 days before total RNA was extracted from 3 wells using
TRIZOL® reagent (Invitrogen, Paisley, UK) according to the
manufacturer’s instructions. Extracted RNA was treated with
RNase-free DNase I (35U/ml) for 30 min at 37°C. The reaction
was terminated by heat inactivation at 65°C for 10 min. Total
RNA was quantified spectrophotometrically by measuring
absorbance at 260nM. RNA was stored at -80°C until
amplification by qPCR.
Quantitative real time polymerase chain reaction
(qPCR)
Osteoblast RNA (50ng) was transcribed and amplified using
the iScript one-step qRT-PCR kit with SYBR green (Biorad
Laboratories Ltd, Hemel Hempstead, UK), which allows cDNA
synthesis and PCR amplification to be carried out sequentially.
qRT-PCR (chromo4, Biorad Laboratories Ltd, Hemel
Hempstead, UK) was performed according to manufacturer’s
instructions with initial cDNA synthesis (50°C for 10 minutes)
and reverse transcriptase inactivation (95°C for 5 minutes)
followed by 40 cycles of denaturation (95°C for 10 seconds)
and detection (60°C for 30 seconds). Gene expression was
investigated in cells cultured for 4, 7 and 14 days. Data were
analysed using the Pfaffl method [39] and are shown as
changes in the level of gene expression relative to that in
untreated cells. All reactions were carried out in triplicate using
RNAs derived from 4 different osteoblast cultures. Primer
sequences are shown in Table 1.
Measurement of pyrophosphate (PPi) levels &
phosphate (Pi) levels
Osteoblasts were cultured until the onset of bone formation.
Culture medium was removed, cell layers washed and cells
incubated in 10mM HEPES buffer containing 0.9% NaCl and
1% bovine serum albumin, pH 7.4 for 1 hour. Apyrase
(0.5-1U/ml) was added to the HEPES buffer and samples
collected 10 minutes after treatment. PPi levels were measured
using an assay which links pyrophosphatase to a phosphate
Table 1.
Gene Primer Sequence (5’–3’)
β actin S gcc ttc ctt cct ggg tat gg
 AS gag gtc ttt acg gat gtc aac g
TNAP S aaa cct aga cac aag cac tc
 AS tcc gat tca act cat act gc
COL1α1 S ggg aca cag agg ttt cag tgg
 AS agc tcc att ttc acc agg act g
NPP1 S aga cca cac ttt tac act ctg
 AS gat gac ctc act gct tac tg
PPARγ S tgc cta tga gca ctt cac ac
 AS atc cat cac aga gag gtc ca
Endogenous ATP and Osteoblasts
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binding colorimetric indicator (PiPer™, Molecular Probes Inc,
Life Technologies, Paisley, UK). Pi levels were assessed using
the Pi ColorLock™ Gold assay kit (Innova Biosciences,
Cambridge, UK). Cell viability was determined by measuring
the amount of LDH in the culture supernatants. All assays were
performed according to the manufacturer’s instructions.
Statistical analysis
Statistical comparisons were made using both parametric
(one-way analysis of variance and adjusted using the
Bonferroni method) and non-parametric (Kruskal-Wallis and
adjusted using the Dunn method) tests. In all figures where
statistical significance is shown both of these methods gave
corresponding results. Representative data are presented as
means ± SEM for six-ten replicates. Results presented are for
representative experiments that were each repeated at least
three times.
Results
Apyrase treatment removes extracellular ATP
The effects of 0.5U/ml apyrase on extracellular ATP levels
were examined in osteoblasts cultured until the onset of bone
formation (~10 days). Within a minute of apyrase treatment, a
rapid decrease in ATP levels was observed; by 2 minutes ATP
levels were negligible and remained so for the duration of the
experiment (10 minutes) (Figure 1A). ATP levels in control
wells remained constant. Extracellular ATP levels were also
measured in osteoblasts cultured with 0.5U/ml apyrase for 4, 7
or 14 days. In control wells, ATP levels were typically in the
range 100-700nM, however, little or no ATP was detected in
apyrase-treated wells (Figure 1B). Cell viability was unaffected
by apyrase treatment (not shown).
Apyrase reduces cell number in the early stages of
osteoblast culture
To determine, whether removing extracellular ATP
influenced cell number in our culture system, osteoblast
number was measured 24, 48 and 72 hours and 7 days after
seeding with/without apyrase (0.5-1U/ml). Cell number was
reduced 30-40% in apyrase-treated cultures at 24, 48 and 72
hours post seeding (Figure 2); by day 7 no differences in
osteoblast number were seen.
Apyrase increases bone mineralisation by osteoblasts
Osteoblasts were cultured with 0.5-2.5U/ml apyrase for up to
14 days. Continuous treatment increased bone formation up to
3-fold (Figure 3A & 3B). The representative images in Figure
3A show low power scans of control and apyrase-treated wells
and higher magnification phase contrast micrographs of the cell
layers. In osteoblast cultures treated with apyrase, the
increased alizarin red staining highlights the increased
formation of mineralised nodules.
Inhibition of vesicular ATP release also increases bone
mineralisation
Since osteoblasts constitutively release ATP, blocking this
process provides another mechanism to study the effects of
endogenous ATP on bone mineralisation. We have previously
shown that vesicular exocytosis inhibitors reduce the release of
ATP from osteoblasts [25]. Osteoblasts were also cultured with
several inhibitors of vesicular exocytosis for up to 14 days.
Acute exposure to NEM (100µM), monensin (≥1µM) and
brefeldin A (100µM) for 1 hour reduced extracellular ATP levels
by ≤ 90%, 55% and 40%, respectively (Figure 4A). Continuous
culture with NEM and brefeldin A (≥1nM) increased bone
formation by up to 50% and 70%, respectively (Figure 4B–4D).
Concentrations of ≥10µM NEM and brefeldin A and ≥10nM
monensin were toxic to osteoblasts and resulted in significant
cell death (not shown).
Apyrase treatment inhibits TNAP activity but does not
affect expression
The activity and expression of TNAP (EC 3.1.3.1), a key
enzyme involved in mineralisation, was examined in apyrase-
treated osteoblasts after 7 and 14 days of culture. TNAP
activity was reduced up to 60% in differentiating osteoblasts
and 40% in mature osteoblasts (Figure 5A). TNAP mRNA
expression (Figure 5B) was unchanged.
Apyrase treatment stimulates total NPP activity
Total NPP activity was examined in osteoblasts cultured with
apyrase for 7 and 14 days. In contrast to TNAP, total NPP
activity was increased up to 50% and 75% in differentiating and
mature osteoblasts, respectively (Figure 5C). NPP1 (EC
3.1.4.1) mRNA expression was unchanged (Figure 5D).
Collagen formation is unchanged by apyrase treatment
In order to determine whether the removal of extracellular
ATP influenced organic matrix synthesis, soluble collagen
levels and expression of COL1α1 mRNA were investigated in
osteoblasts at 7 and 14 days of culture. In both differentiating
and mature cells, soluble collagen levels (Figure 5E) and
COL1α1 mRNA expression (Figure 5F) were unaffected.
Treatment with apyrase does not influence adipocyte
formation
To establish whether eliminating extracellular ATP influenced
the differentiation of precursor cells towards the adipogenic
rather than osteogenic lineage, adipocyte formation was
quantified in apyrase treated cells using oil red O staining. At
both 7 and 14 days of culture, the level of oil red o staining was
unchanged (Figure 5G). Expression of the adipogenic
transcription factor, PPARγ, was also unaffected by the
removal of extracellular ATP (Figure 5H).
Apyrase treatment alters the levels of Pi and PPi in the
culture medium
The ratio of extracellular Pi to PPi plays an important role in
the rate of mineralisation. Thus, Pi and PPi levels were
assessed in osteoblasts treated with apyrase (0.5-1U/ml). PPi
Endogenous ATP and Osteoblasts
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 levels were decreased by 3-4µM (Figure 6A) whilst Pi levels
were increased by ~10-15µM (Figure 6D).
Inhibition of P2X1 and P2X7 receptor mediated
signalling increases bone mineralisation
Reduced signalling at the P2 receptors associated with the
inhibition of bone mineralisation (P2Y2, P2X1, P2X7) could
contribute towards the increased bone mineralisation seen with
apyrase. Thus osteoblasts were cultured with a number of
P2X1 and P2X7 receptor antagonists to directly study the
effects of decreased receptor signalling. There are currently no
selective P2Y2 receptor antagonists commercially available.
The P2X1 receptor antagonist, Ro-0437626 (Figure 7A),
doubled the level of bone mineralisation, whilst the other
antagonists NF279 (Figure 7B) and PPNDS (Figure 7C)
(≥1µM) increased bone mineralisation by ≥ 50% and 70%,
respectively. The P2X7 receptor antagonists ≥1µM
AZ10606120 (Figure 7D), ≥0.1µM A740003 (Figure 7E) and
≥10µM A804598 (Figure 7F) increased bone mineralisation by
~80%, ~80% and 40%, respectively. Higher concentrations of
AZ10606120 (≥ 10µM) resulted in a reduction in the amount of
bone mineralisation (Figure 7D); this inhibition was not seen
with any other P2X7 receptor antagonists.
Discussion
Significant roles for extracellular nucleotides in the regulation
of bone cell function are now emerging [6–8]. Most of the in
vitro studies performed to date have involved the addition of
exogenous ATP to the culture medium. Here, we provide
evidence that locally produced ATP is a key regulator of bone
mineralisation via both P2 receptor dependent and
independent mechanisms.
Figure 1.  Apyrase treatment removes extracellular ATP.  (A) Within one minute of 0.5U/ml apyrase treatment, a rapid decrease
in ATP levels was observed; by 2 minutes and for the remainder of the experiment (10 minutes) ATP levels were negligible. ATP
levels in control wells remained relatively constant. (B) ATP levels were measured in osteoblasts cultured with 0.5U/ml apyrase for
4, 7 or 14 days. In the controls wells, ATP levels were between 100–700nM; little or no ATP was detected in apyrase-treated wells.
Values are means ± SEM (n=8-10 replicate wells), *** = p <0.001.
doi: 10.1371/journal.pone.0069057.g001
Endogenous ATP and Osteoblasts
PLOS ONE | www.plosone.org 5 July 2013 | Volume 8 | Issue 7 | e69057
Apyrase is a broad spectrum NTPDase which rapidly
hydrolyses NTPs and NDPs to their corresponding NMP and Pi
[29]. In normal osteoblast cultures, the half-life of
endogenously-released extracellular ATP is ~10 minutes [25];
however, its downstream effects are likely to be longer lasting
[40]. Addition of apyrase to tissue culture medium provided an
in vitro environment where extracellular nucleotides were
rapidly hydrolysed (half-life ~ 30 seconds), allowing the role of
locally released ATP in the regulation of osteoblast function to
be studied. The fast removal of ATP and ADP will likely
influence local purinergic signalling as extracellular nucleotides
will be degraded before they can bind to and activate P2
Figure 2.  Apyrase treatment reduces osteoblast number in the early stages of culture.  Osteoblast number was measured 24,
48 and 72 hours and 7 days after seeding with/without apyrase (0.5-1U/ml). Cell number was reduced 30-40% in apyrase-treated
cultures at 24, 48 and 72 hours. Values are means ± SEM (n=6 replicate wells), *** = p <0.001, ** = p <0.01, * = p <0.05.
doi: 10.1371/journal.pone.0069057.g002
Endogenous ATP and Osteoblasts
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receptors. It could also affect local P1 receptor signalling due to
an increased accumulation of adenosine. Furthermore, it will
shift the extracellular Pi/PPi ratio in favour of Pi, as nucleotides
will preferentially be degraded by apyrase to produce Pi rather
than by NPP1 to produce PPi.
The most significant effect of the removal of endogenous
ATP by apyrase was the strikingly increased formation of
mineralised bone nodules. The lack of effect of apyrase
treatment on collagen production indicates that this osteogenic
effect was due primarily to enhanced mineralisation. This
finding is consistent with earlier observations that exogenous
extracellular nucleotides selectively inhibit mineralisation in
vitro [20,21]. This effect occurs via dual mechanisms: firstly,
ATP acts via the P2Y2, P2X1 and P2X7 receptors to inhibit
TNAP expression and activity and, secondly, it can be directly
hydrolysed by NPP1 to increase the local concentration of the
physicochemical mineralisation inhibitor, PPi [20,21].
Selective P2X1 and P2X7 receptor antagonists were used to
study the role of these receptors in the regulation of bone
mineralisation by endogenous ATP. At present, there are no
selective P2Y2 receptor antagonists available and so a
pharmacological approach to studying this receptor was not
possible. Since many of these “selective” antagonists are likely
to have some (albeit small) effects on other P2 receptor
subtypes, we tested a number of different compounds. Our
data showing that three different P2X1 and P2X7 receptor
antagonists increased bone mineralisation suggest that locally
released ATP acts via these receptors to regulate bone
mineralisation. The extent to which individual antagonists
promoted bone mineralisation was variable, most probably
reflecting differences in potency, selectivity and/or binding. One
P2X7 receptor antagonist, AZ10606120, caused a reduction in
mineralisation at ≥ 10µM. This inhibition was not seen with any
of the other P2X7 receptor antagonists and might therefore
reflect non-selective cell toxicity rather than specific effects on
P2X7 receptor signalling.
The ability of the abovementioned P2 antagonists to promote
bone mineralisation is consistent with our earlier findings
implicating the P2X1 and P2X7 receptors in the regulation of
bone mineralisation by extracellular nucleotides [21]. Whilst
signalling via the P2X1 receptor appears to regulate bone
mineralisation directly, the role of the P2X7 receptor may be
Figure 3.  Apyrase treatment increases bone mineralisation.  The images in (A) are representative of control and apyrase-
treated osteoblast cell layers (left, low power whole well scans; right, higher magnification phase contrast micrographs). The
widespread alizarin red staining highlights the increased formation of mineralised nodules. Scale bars = 0.25cm and 50µm. (B)
Continuous treatment for 14 days with 0.5-2.5U/ml apyrase increased bone formation up to 3-fold. Values are means ± SEM (n=6
replicate wells), *** = p <0.001, ** = p <0.01, * = p <0.05.
doi: 10.1371/journal.pone.0069057.g003
Endogenous ATP and Osteoblasts
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more complex. This is because ATP release from osteoblasts
involves efflux via the P2X7 receptor [27]; thus, the effects of
P2X7 receptor inhibition on bone mineralisation could be due to
a direct inhibition of receptor-mediated signalling and/or a
secondary effect due to reduced ATP release. These findings
are, however, at variance with the reduced mineral deposition
reported for cultures of osteoblasts isolated from P2X7
receptor-deficient mice [14]. The reasons behind this
discrepancy are unclear but may reflect the different species
used (rat versus mouse), variations in cell culture protocols, the
complex nature of the P2X7 receptor and its polymorphisms
and potential cross-talk between receptor antagonists. Further
studies are needed to clarify the role of this receptor in bone
mineralisation.
Figure 4.  Inhibitors of vesicular ATP release increase bone mineralisation.  (A) Treatment with NEM (100µM), monensin
(≥1µM) and brefeldin A (100µM) for 1 hour reduced extracellular ATP levels by up to 90%, 55% and 40%, respectively. (B) Culture
with NEM (≥1nM) for 14 days increased bone formation by up to 50%. (C) In osteoblasts treated with brefeldin A, bone formation
was increased up to 70%. Values are means ± SEM (n=8-10 replicate wells), *** = p <0.001, ** = p <0.01, * = p <0.05). (D) Phase
contrast microscopy images showing the increased mineralised bone nodule formation in osteoblast cultures treated with 100nM
NEM and brefeldin A. Scale bar = 50µm.
doi: 10.1371/journal.pone.0069057.g004
Endogenous ATP and Osteoblasts
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Figure 5.  Apyrase treatment inhibits TNAP activity but increases total NPP activity.  (A) TNAP activity was reduced up to
60% in differentiating osteoblasts and 40% in mature osteoblasts. (B) TNAP mRNA expression were unchanged by apyrase
treatment. (C) Total NPP activity was increased up to 50% and 75% in differentiating and mature osteoblasts, respectively. (D)
Apyrase did not influence NPP1 mRNA expression. (C) Soluble collagen levels and (E) COL1α1 mRNA expression were unchanged
by apyrase treatment in both differentiating and mature osteoblasts. (F) Oil red O staining for adipocytes and (G) expression of the
adipogenic transcription factor, PPARγ, were unchanged in apyrase treated cells. Values are means ± SEM (n=6 replicate wells or 4
RNA sets), *** = p <0.001, ** = p <0.01, * = p <0.05.
doi: 10.1371/journal.pone.0069057.g005
Endogenous ATP and Osteoblasts
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Within the bone microenvironment, TNAP and NPP1 work
antagonistically to maintain the extracellular Pi/PPi ratio and
prevent hyper- or hypomineralisation [30,31]. Addition of
micromolar ATP concentrations to osteoblast cultures inhibits
TNAP expression and activity in vitro [20]. Given this earlier
finding and the increased bone mineralisation observed in
apyrase-treated cultures, the inhibition of TNAP activity and
unchanged mRNA expression was unexpected. Furthermore,
NPP activity was increased following apyrase treatment. Earlier
work has shown that Pi and PPi can inhibit TNAP activity [41].
Thus, one possible explanation for this apparent discrepancy is
that the rapid and artificial apyrase-mediated increase in Pi
levels causes a product-mediated negative feedback to inhibit
TNAP activity, whilst the low levels of PPi cause an increase in
NPP activity in an attempt to return the Pi/PPi ratio to normal.
The question of whether apyrase treatment influences the
expression and activity of other potentially important ATP-
degrading enzymes, such as ecto-5’-nucleotidase, will need to
be examined in a future study.
The major source of extracellular ATP is normally controlled
release from cells (rather than via cell death); cell culture
medium ATP levels are typically measured in the nanomolar
range [25]. All three types of bone cell, osteoblasts [22–26],
osteoclasts [27] and MLO-Y4 osteocyte-like cells [28] release
ATP in a constitutive manner. ATP release from osteoblasts
occurs primarily via vesicular exocytosis [25], although the
P2X7 receptor is also involved [27]. Blocking ATP release with
inhibitors of vesicular exocytosis provides another method for
studying the effects of reduced extracellular ATP on osteoblast
function. We found that both NEM, which inhibits fusion of
vesicles with the plasma membrane, and brefeldin A, which
disrupts protein transport between the endoplasmic reticulum
and the Golgi apparatus, increased bone mineralisation in
osteoblast cultures. Interestingly, the concentrations at which
these inhibitors increased bone mineralisation (1nM-1µM) were
significantly lower than the levels which acutely inhibit ATP
release (>1µM). Prolonged culture with ≥10µM NEM and
brefeldin A and ≥10nM monensin was toxic to osteoblasts and
resulted in significant cell death, possibly due to the
intracellular accumulation of ATP. Thus, the lower
concentration of NEM and brefeldin A may reduce ATP release
enough to influence bone formation but, given that ATP levels
are measured in several ml of media, not enough to be
detected via the luciferin-luciferase assay.
Figure 6.  Apyrase treatment influences Pi and PPi levels in osteoblast culture medium.  (A) PPi levels were decreased 4-fold
(3-4µM) and (B) Pi levels were increased 0.5-fold (~15µM). Cell viability was unchanged throughout. Values are means ± SEM (n=6
replicate wells), *** = p <0.001, ** = p <0.01, * = p <0.05.
doi: 10.1371/journal.pone.0069057.g006
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Figure 7.  P2X1 and P2X7 receptor antagonists increase bone mineralisation.  (A) Culture with the P2X1 receptor antagonist,
≥0.1µM Ro-0437626 doubled the level of bone mineralisation. Treatment with other P2X1 receptor antagonists (≥1µM) (B) NF279
and (C) PPNDS increased bone mineralisation by ≥ 50% and 70%, respectively. The P2X7 receptor antagonists (D) ≥1µM
AZ10606120, (E) ≥0.1µM A740003 and (F) ≥10µM A804598 increased bone mineralisation by ~80%, ~80% and 40%, respectively.
Values are means ± SEM (n=6 replicate wells), *** = p <0.001, ** = p <0.01, * = p <0.05.
doi: 10.1371/journal.pone.0069057.g007
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Previous work showed that ATP stimulates the proliferation
of osteoblast-like cells [10]. In agreement, we found that
elimination of extracellular ATP by apyrase resulted in small
decreases in osteoblast numbers during the early, proliferative
stages of culture. No differences in cell number were observed
by day 7, suggesting that the removal of extracellular ATP
retards cell growth, rather than inducing apoptosis. Thus as
growth rates slow, which is commonly seen in these osteoblast
cultures from ~ day 7 [35], the apyrase-treated cells effectively
catch up.
Recent studies have implicated extracellular nucleotides and
purinergic signalling in the control of mesenchymal stem cell
differentiation into osteoblasts or adipocytes [16,17]. We found
that removal of endogenous extracellular nucleotides by
apyrase did not affect the level of adipocyte formation or
PPARγ expression. This indicates that ATP is not a significant
regulator of osteogenic/adipogenic differentiation in the rat
calvarial osteoblast model. It should be noted that because the
calvarial cells are treated with dexamethasone to promote the
formation of osteoblasts [42] the basal adipocyte formation in
these cultures is relatively low. Therefore, the apparent lack of
effect of extracellular nucleotides on differentiation could be
because the cells used here were more committed to the
osteoblast lineage than mesenchymal stem cells.
There is increasing interest in the potential roles of
adenosine, AMP and P1 receptor-mediated signalling in the
regulation of bone cell function [43]. For example, it has been
reported that adenosine is mitogenic to osteoblast-like cells
[44] and may influence the differentiation of osteoprogenitor
cells in vitro [45]. Given that apyrase treatment would be
expected to cause increased levels of extracellular adenosine,
it is plausible that some of the effects we observed here were
due to altered P1 receptor signalling. However, we have
previously shown that adenosine and AMP have no effects on
the function of rat calvarial osteoblasts [19]. This suggests that
the effects of apyrase on mineralisation are unlikely to be due
to increased adenosine or AMP levels following the rapid
hydrolysis of ATP. Thus our data indicate that the increased
bone mineralisation seen in apyrase-treated cultures is
probably because the reduction in extracellular ATP decreases
both P2 receptor-mediated signalling and alters the
extracellular Pi/PPi concentration.
In summary, the work presented here shows that ATP
released from osteoblasts acts via P2 receptors or degradation
by NPP1 to produce PPi, so as to function as an endogenous
restraint on bone mineralisation. Our findings also raise the
interesting question of whether ATP released from osteocytes
could be hydrolysed to PPi and thus act to prevent
hypermineralisation within bone. Furthermore, since ATP is
released constitutively from most cell types these data raise the
possibility that extracellular ATP may act to prevent the
mineralisation of soft tissues.
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